Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0L0GM
|
|||
Former ID |
DNCL002047
|
|||
Drug Name |
Vilanterol
|
|||
Synonyms |
503068-34-6; GW642444x; UNII-028LZY775B; GW-642444x; CHEBI:75037; 028LZY775B; Vilanterol (GW642444; GW 642444X); 4-((1R)-2-((6-(2-((2,6-dichlorophenyl)methoxy)ethoxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol; 4-[(1R)-2-[(6-{2-[(2,6-dichlorophenyl)methoxy]ethoxy}hexyl)amino]-1-hydroxyethyl]-2-(hydroxymethyl)phenol; Vilanterol [USAN:INN]; vilanterolum; Vilanterol base; Vilanterol (USAN); SCHEMBL142630; GTPL7353; CHEMBL1198857; DTXSID80198318; DAFYYTQWSAWIGS-DEOSSOPVSA-N; MolPort-044-560-195; Relovair
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Approved | [1], [2], [3] | |
Company |
GlaxoSmithKline
|
|||
Structure |
Download2D MOL |
|||
Formula |
C24H33Cl2NO5
|
|||
Canonical SMILES |
C1=CC(=C(C(=C1)Cl)COCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O)Cl
|
|||
InChI |
1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1
|
|||
InChIKey |
DAFYYTQWSAWIGS-DEOSSOPVSA-N
|
|||
CAS Number |
CAS 503068-34-6
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:75037
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adrenergic receptor beta-2 (ADRB2) | Target Info | Modulator | [1] |
KEGG Pathway | Calcium signaling pathway | |||
cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Endocytosis | ||||
Adrenergic signaling in cardiomyocytes | ||||
Salivary secretion | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Beta2 adrenergic receptor signaling pathway | ||||
Pathway Interaction Database | Arf6 trafficking events | |||
Arf6 signaling events | ||||
Reactome | Adrenoceptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Monoamine GPCRs | |||
Calcium Regulation in the Cardiac Cell | ||||
GPCRs, Class A Rhodopsin-like | ||||
Vitamin D Receptor Pathway | ||||
GPCR ligand binding | ||||
GPCR downstream signaling | ||||
GPCRs, Other |
References | Top | |||
---|---|---|---|---|
REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353). | |||
REF 2 | ClinicalTrials.gov (NCT01936649) Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.. U.S. National Institutes of Health. | |||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.